SCHEMBL20117073

SCHEMBL20117073

CC1(C)CC1C(=O)N1CCC(c2noc(-c3ccc4cnn(C5COC5)c4c3)n2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP7 Q93009 1/20 0.40
USP30 Q70CQ3 2/20 0.38
HTT P42858 1/20 0.38
TBK1 Q9UHD2 3/20 0.36
PIK3CD O00329 2/20 0.36
KIT P10721 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35
SMO Q99835 1/20 0.35
IDO1 P14902 1/20 0.35
WNT1 P04628 1/20 0.35
GSK3B P49841 1/20 0.35
DYRK1A Q13627 1/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
RAB9A P51151 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20676311 0.89 TBK1 (0.45) USP7USP30HTTTBK1PIK3CD
SCHEMBL20116521 0.87 USP7 (0.38) USP7USP30HTTTBK1PIK3CD
SCHEMBL20116396 0.87 TBK1 (0.46) USP7USP30HTTTBK1SMN1; SMN2
SCHEMBL20116089 0.87 SMO (0.42) USP7USP30HTTTBK1PIK3CD
SCHEMBL20116522 0.86 USP7 (0.41) USP7USP30HTTTBK1PIK3CD
SCHEMBL20116423 0.86 FASN (0.43) USP7USP30HTTTBK1PIK3CD
SCHEMBL20116305 0.86 USP7 (0.41) USP7USP30HTTTBK1PIK3CD
SCHEMBL20676660 0.86 USP7 (0.41) USP7USP30HTTTBK1PIK3CD
SCHEMBL22358068 0.86 USP7 (0.38) USP7USP30HTTTBK1PIK3CD
SCHEMBL20116381 0.86 USP30 (0.38) USP7USP30HTTTBK1PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 USP7 4265/4885USP30 3526/4885HTT 6/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 USP7 4265/4885USP30 3526/4885HTT 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.